At-home brain stimulation has FDA approval, but clinical proof remains thin

The FDA’s clearance of Flow Neuroscience’s at-home transcranial direct-current stimulation headset marks a notable step for neuromodulation as a depression treatment, but the evidence remains more suggestive than decisive, reports the New York Times. The device delivers a weak electric current to the brain and is being promoted as a possible alternative or supplement to SSRIs, especially because it can be used at home rather than in a clinic.

The clinical case, however, is mixed. Earlier tDCS research has produced modest and inconsistent results, and a 2024 study found Flow’s device no more effective than internet browsing as a placebo. The FDA-backed Empower trial was more encouraging but still limited: 174 participants used the device remotely, and the primary outcome showed only a “minor” improvement on the Hamilton depression scale. FDA reviewers also cited “a moderate level of uncertainty of benefit” because many participants could tell whether they were receiving real stimulation or placebo.

Secondary outcomes were stronger—58 percent response with treatment versus 38 percent in controls, and 45 percent remission versus 22 percent—but those findings do not yet prove tDCS can meaningfully reduce psychiatry’s reliance on SSRIs. For now, the device looks less like a pill-box revolution than an early-stage adjunct: promising, relatively low-risk, and clinically interesting, but not yet a proven substitute for established depression treatments.